TIP or BEP for Intermediate or Poor Risk Testicular Cancer?: Highlights in GU Oncology from ASCO 2018 (BMIC-061)

TIP or BEP for Intermediate or Poor Risk Testicular Cance...
Dr. Dan Goldstein reviews results of a trial of chemo regimen TIP (paclitaxel, ifosfamide, cisplatin) vs BEP (bleomycin, etoposide, cisplatin) for intermediate/poor risk germ cell tumors, with discussion of outcomes in patients with a p53 mutation.
355 Views
4 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login

Testicular

Jonathan Shamash MBChB, MD, MRCP @NHSBartsHealth @NHSEnglandLDN #TesticularCancer #Cancer #Research The Impact Of A SMDT On Decision- Making in Testicular Cancers
Jonathan Shamash MBChB, MD, MRCP @NHSBartsHealth @NHSEngl...
58 Views
1 year ago
Cancer
Want to watch this again later?
Sign in to add this video to a playlist. Login
Molecular aging and p16INK4a in testicular cancer survivors
Molecular aging and p16INK4a in testicular cancer survivors
229 Views
4 years ago
VJ
Want to watch this again later?
Sign in to add this video to a playlist. Login
TIP or BEP for Intermediate or Poor Risk Testicular Cancer?: Highlights in GU Oncology from ASCO 2018 (BMIC-061)
TIP or BEP for Intermediate or Poor Risk Testicular Cance...
355 Views
4 years ago
H. Jack
Want to watch this again later?
Sign in to add this video to a playlist. Login